The National Institute for Health and Clinical Excellence has recommended that bevacizumab, sorafenib, sunitinib and temsirolimus should not be treatment options for advanced or metastatic renal cell carcinoma.
The initial decision, which is subject to further consultation, was criticised by groups including Cancer Research UK.
See the NICE consultation documents at www.nice.org.uk
Insider tales and must-read analysis on how integration is reshaping policy, providers, primary care, and commissioning. This week by HSJ commissioning correspondent Sharon Brennan.
Infection prevention has vital benefits such as tackling the antimicrobial resistance crisis as well as benefitting patients, staff and healthcare providers. By Jennie Wilson
The prices of certain generic drugs are “seeing another surge” which could have a significant impact on the finances of NHS commissioners, a pharmacy body has warned.
We are aware that some of our users are experiencing problems accessing hsj.co.uk.
To protect your security as hsj.co.uk upgrades to a new platform, your existing password will no longer work.
Financial penalties are being lifted from high-profile standards including cancer and elective waiting times, so far without attracting much attention. How is this happening? And will it work, asks Rob Findlay
No comments yet